CXCR3 (also known as G protein-coupled receptor 9 (GPR9) and CD183) is a chemokine receptor predominantly expressed in T lymphocytes. It is also expressed on natural killer cells and some epithelial cells. Among its agonists are CXCL9, CXCL10 and CXCL11, all IFN-γ-inducible chemokines that promote Th1 responses.
CXCR3 therefore plays an important role in immune response and inflammation. Specifically, it is involved with leukocyte trafficking, with CXCR3-ligand interaction playing a role in the attraction and maturation of a subset of T lymphocytes (Th1).
CXCR3 has been implicated in a number of diseases, including:
- Multiple Sclerosis
- Pulmonary fibrosis
- Type 1 diabetes
- Other autoimmune diseases
CXCR3 is therefore a target of research interest, particularly in the development of therapeutics that target the CXCR3-ligand interaction.
A murine pre-B cell line L1.2 has been transformed to express human CXCR3. This allows experiments targeting CXCR3-ligand interactions to be performed on a mammalian cell line, but without the additional restrictions of those cells being human. This cell line has been used in a number of peer-reviewed publications.
The cell line has been developed by Dr James Pease and colleagues at Imperial College London.
+44 (0)20 7594 6866